Drug intelligence / Profile preview

autologous tolerogenic dendritic cells (SARS-CoV-2)

Development stage: Preclinical
Lead developer: DiaVacs
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

This autologous cell therapy consists of tolerogenic dendritic cells (DC regs) engineered to downregulate the costimulatory molecules CD40, CD80, and CD86. Developed by Nick Giannoukakis, PhD, and DiaVacs, the therapy utilizes antisense oligodeoxynucleotides (AS-ODNs) to modify the dendritic cells, inducing a state of antigen-specific immunomodulation. While the platform was originally designed to treat autoimmune conditions like Type 1 Diabetes by suppressing the immune attack on pancreatic beta cells, it is being investigated as a treatment for SARS-CoV-2 infection to modulate the inflammatory response. The candidate is currently in preclinical development for COVID-19.

Other names: Nick Giannoukakis, PhD-CD40-CD80-CD86-cell therapy-SARS-CoV-2tolerogenic dendritic cellsDC regs (SARS-CoV-2)

Targets

CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)CD40 (Cluster of differentiation 40 receptor)SARS-CoV-2-specific T-cell

Beyond the preview

Go deeper on autologous tolerogenic dendritic cells (SARS-CoV-2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous tolerogenic dendritic cells (SARS-CoV-2).

Explore the full profile